1315 Capital, LLC, a Philadelphia, PA-based expansion and growth equity firm, added senior investment professional Edward Chan to its team.
Mr. Chan brings to 1315 Capital extensive investing experience across late stage venture and lower middle market transactions.
Prior to joining 1315, Mr. Chan spent nearly five years at NaviMed Capital, a lower middle market healthcare fund based in Washington, D.C. Most recently, he was a Vice President and focused on identifying and executing investments across healthcare services, healthcare IT and medical products.
Prior to joining NaviMed Capital, Mr. Chan spent three years at Siemens Venture Capital. Based out of Boston and Beijing, he evaluated and sourced commercial and growth stage healthcare deals worldwide, performed research on various market sectors and supported portfolio companies.
While at NaviMed and Siemens, Mr. Chan was actively involved in the following investments: CenterPointe Behavioral Health System, Lucent Health Solutions, China Diagnostics Medical Corporation (sold to Actis Capital), BioImagene (sold to Roche), RadPharm (sold to JLL Partners), U-Systems (sold to GE), MD Datacor (sold to Noridian Mutual Insurance), Zonare (sold to Mindray), Sequenom (sold to LabCorp) and Cylex (sold to Viracor-IBT).
He also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular and started his career developing and commercializing a molecular diagnostic product at a venture backed company.
Co-founded by Adele Oliva and Michael Koby, 1315 Capital invests in commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies.